As the world economy suffers from an unprecedented sanitary crisis, the outlook is blurred for the vibrant though fragile European biotech ecosystem. Can life-science investors support innovators financing needs from seed to A/B rounds? What to expect from stock-exchange in Europe and US? Will big pharma take the risk of partnership and M&A in the current environment? How big is the place of biotech in a post-COVID-19 world?